Abstract:PurposeTo determine the safety and efficacy of transarterial yttrium-90 (490Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma.Materials and MethodsThis is a single institution retrospective cohort study of patients with intrahepatic cholangiocarcinoma who were treated with transarterial 490Y radioembolization between October 2009 and April 2014. 68 patients (30 males, 38 females, median age of 71) identified. 48 patients (70.5%) received systemic chemotherapy prior to radioembolization. Primary endpoints included biochemical and clinical toxicities, and overall survival from time of radioembolization.ResultsA total of 114 radioembolization treatments were performed in 68 patients. The average radiation dose delivered was 176.9±86.7 Gy (mean±SD). At 1 month follow-up there was no major complications. Forty-nine patients (72%) reported grade 1 or 2 toxicities (mostly fatigue, nausea, anorexia, abdominal pain, fever) at 1 month follow-up. Radioembolization treatment had no significant effect on liver functions at 1 month. Patients' pre-radioembolization MELD scores slightly increased from 7.1±1.69 (mean±SD) to 7.7±2.97 (mean±SD). Thirty-six patients were alive at 6-month post-treatment and 3 patients had jaundice, 2 patients had ascites and 1 had portal vein thrombosis and 58% of patients had grade 1 or 2 toxicities. The MELD score was 8.6±4.9 (mean±SD) at 6 months. The median overall survival from time of the first radioembolization treatment was 11.7 months (95% CI of 7.1-18.8).ConclusionTransarterial 490Y radioembolization is safe treatment option and provides survival benefit in patients with intrahepatic cholangiocarcinoma. PurposeTo determine the safety and efficacy of transarterial yttrium-90 (490Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma. To determine the safety and efficacy of transarterial yttrium-90 (490Y) radioembolization in patients with unresectable intrahepatic cholangiocarcinoma. Materials and MethodsThis is a single institution retrospective cohort study of patients with intrahepatic cholangiocarcinoma who were treated with transarterial 490Y radioembolization between October 2009 and April 2014. 68 patients (30 males, 38 females, median age of 71) identified. 48 patients (70.5%) received systemic chemotherapy prior to radioembolization. Primary endpoints included biochemical and clinical toxicities, and overall survival from time of radioembolization. This is a single institution retrospective cohort study of patients with intrahepatic cholangiocarcinoma who were treated with transarterial 490Y radioembolization between October 2009 and April 2014. 68 patients (30 males, 38 females, median age of 71) identified. 48 patients (70.5%) received systemic chemotherapy prior to radioembolization. Primary endpoints included biochemical and clinical toxicities, and overall survival from time of radioembolization. ResultsA total of 114 radioembolization treatments were performed in 68 patients. The average radiation dose delivered was 176.9±86.7 Gy (mean±SD). At 1 month follow-up there was no major complications. Forty-nine patients (72%) reported grade 1 or 2 toxicities (mostly fatigue, nausea, anorexia, abdominal pain, fever) at 1 month follow-up. Radioembolization treatment had no significant effect on liver functions at 1 month. Patients' pre-radioembolization MELD scores slightly increased from 7.1±1.69 (mean±SD) to 7.7±2.97 (mean±SD). Thirty-six patients were alive at 6-month post-treatment and 3 patients had jaundice, 2 patients had ascites and 1 had portal vein thrombosis and 58% of patients had grade 1 or 2 toxicities. The MELD score was 8.6±4.9 (mean±SD) at 6 months. The median overall survival from time of the first radioembolization treatment was 11.7 months (95% CI of 7.1-18.8). A total of 114 radioembolization treatments were performed in 68 patients. The average radiation dose delivered was 176.9±86.7 Gy (mean±SD). At 1 month follow-up there was no major complications. Forty-nine patients (72%) reported grade 1 or 2 toxicities (mostly fatigue, nausea, anorexia, abdominal pain, fever) at 1 month follow-up. Radioembolization treatment had no significant effect on liver functions at 1 month. Patients' pre-radioembolization MELD scores slightly increased from 7.1±1.69 (mean±SD) to 7.7±2.97 (mean±SD). Thirty-six patients were alive at 6-month post-treatment and 3 patients had jaundice, 2 patients had ascites and 1 had portal vein thrombosis and 58% of patients had grade 1 or 2 toxicities. The MELD score was 8.6±4.9 (mean±SD) at 6 months. The median overall survival from time of the first radioembolization treatment was 11.7 months (95% CI of 7.1-18.8). ConclusionTransarterial 490Y radioembolization is safe treatment option and provides survival benefit in patients with intrahepatic cholangiocarcinoma. Transarterial 490Y radioembolization is safe treatment option and provides survival benefit in patients with intrahepatic cholangiocarcinoma.

Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma

Twenty Years of Radiation Therapy of Unresectable Intrahepatic Cholangiocarinoma: Internal or External? A Systematic Review and Meta-Analysis

Selective Internal Radiotherapy in Liver Tumors: Early Promise Yet to be Fulfilled

The Safety and Short-Term Efficacy of Selective Internal Radiation Therapy Combined with Systemic Treatment for Unresectable Malignant Hepatic Tumors in Chinese Patients.

Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases

Intrahepatic Cholangiocarcinoma Treated with Transarterial Yttrium-90 Radioembolization - the Moffitt Experience

Chronic gastric ulcer disease complicating selective internal radiation therapy (SIRT) in a patient with cholangiocellular carcinoma

Selective internal radiation therapy for hepatocellular carcinoma: A 15-year multicenter Australian cohort study

Safety and Efficacy of Selective Internal Radionuclide Therapy with 90Y Glass Microspheres in Patients with Progressive Hepatocellular Carcinoma after the Failure of Repeated Transarterial Chemoembolization

Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres Followed by Anatomical Hepatectomy: A Potential Curative Strategy in Advanced Hepatocellular Carcinoma

Single-institutional analysis of radiotherapy and orthotopic liver transplant for patients with unresectable cholangiocarcinoma.

Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors

Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases

Selective internal radiation therapy segmentectomy: A new minimally invasive curative option for primary liver malignancies?

Percutaneous Ultrasound-Guided Thermal Ablation for Intrahepatic Cholangiocarcinoma.

Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis

Adrenocortical carcinoma: selective internal radiation therapy and liver metastases

[Expert consensus on the standardized procedure of selective internal radiation therapy with Yttrium-90 microspheres for liver malignancies (2024 edition)]

Hepatic arterial infusion of 32P-glass microspheres (32P-GMS) in the treatment of unresected primary liver carcinoma

Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy

Safety and Efficacy of 90Y Selective Internal Radiation Therapy Using Glass Microspheres in Hepatocellular Carcinoma: A Southeast Asian Single-Institution Initial Experience